Newsroom


Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen) in the European Union

Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen) in the European Union

TEGSEDI™ (inotersen) has received marketing authorization approval from the European Commission (EC) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR).

TEGSEDI™ is now the world’s first and only RNA-targeted therapeutic approved for patients with hATTR amyloidosis. This drug brings significant benefits in both measures of neuropathy and quality of life for people living with this rare disease.

Read the complete press release here.